Pacific Biosciences of California, Inc.
PACB· Nasdaq
PACBPacific Biosciences of California, Inc.
Released Aug 7, 2024, after the close
10-Q filed Aug 9, 2024, 40 days after period end · 0001299130-24-000169
| Metric | Q2 2024 | Q2 2023 | Q2 2022 | Q2 2021 |
|---|---|---|---|---|
| Revenue | $36.01M | $47.57M | $35.47M | $30.61M |
| Net Income | -$173.32M | -$69.83M | -$71.39M | -$41.00M |
| EPS Diluted |
Pacific Biosciences of California, Inc. · CIK 1299130 · Engraved from SEC EDGAR
| -$0.64 |
| -$0.28 |
| -$0.32 |
| -$0.21 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
